Key result
Pulmonary hypertension remains linked to ~15% higher mortality, a risk attenuated by increased GDMT use.
Why the study?
Pulmonary hypertension is a key prognostic marker in HF with challenging management, but how its prognostic impact on mortality has evolved over time was unknown.
Does the presence of pulmonary hypertension increase mortality risk in heart failure patients, and has this prognostic impact evolved over time?
Cohort (n=32,902)
No
Does the presence of pulmonary hypertension increase mortality risk in heart failure patients, and has this prognostic impact evolved over time?
The mortality risk associated with pulmonary hypertension in heart failure patients has significantly attenuated in recent years, likely reflecting the increased adoption of guideline-directed medical therapies such as SGLT2 inhibitors, MRAs, and ARNIs.
Answers are grounded in this paper and cite their sources.
PH-associated mortality risk in HF attenuated since 2016; extends prior associations but leaves causal impact of GDMT open.
Introduction Pulmonary hypertension (PH) is a key prognostic marker in heart failure (HF), yet its management remains challenging, particularly in elderly populations. This study evaluates trends in mortality among HF patients and examines how the prognostic impact of PH has evolved over more than a decade. Purpose To analyze the evolving impact of PH on mortality in HF patients over different time periods and evaluate changes in treatment strategies. Methods A retrospective cohort study was conducted on HF patients treated from 2009 to August 2024 at a single tertiary center, including both ambulatory and hospitalized patients. Kaplan-Meier survival analysis and Cox proportional hazards models were applied. Patients were stratified by PH (defined as estimated systolic pulmonary artery pressure ≥40 mmHg) and time period (before and after June 2016). Ethical approval was obtained from the Institutional Review Board. Results The cohort included 32,902 patients (median age 72 years [IQR 64–82]), 19,168 (58%) males, of whom 14,627 (44%) had PH (median SPAP 44 mmHg [IQR 33–52]). Over a median follow-up of 5 years (IQR 1–7), 18,558 (56%) patients died. Treatment strategies evolved significantly, with increased adoption of sodium-glucose cotransporter inhibitors-2 (12% vs. 1.4%), mineralocorticoid receptor antagonists (26% vs. 6%), and angiotensin receptor/neprilysin inhibitors (11.5% vs. 3.5%). Compared with no PH, PH patients had a 40% higher mortality risk (HR 1.40, 95% CI 1.29–1.52, p < 0.001). Median SPAP did not change significantly between early and late time periods (44 ±14.5 and 43.5 ± 14.5). However, interaction analysis showed PH-associated mortality risk was period-dependent, and decreased significantly from 40% in the early time period to only 15% in the late time period (95% CI 1.28–1.52 vs. 1.02–1.31, p for interaction = 0.015). Conclusions PH remains a significant predictor of mortality in contemporary HF patients. However, its impact has attenuated in recent years, potentially reflecting the adoption of guideline-directed medical therapy. These findings emphasize the need for continued innovation in HF management to improve outcomes for patients with PH.
No takes yet. Share an insight, caveat, or question.
Copeland et al. (2025) conducted a cohort in Heart failure (n=32,902). Pulmonary hypertension vs. No pulmonary hypertension was evaluated on Mortality (HR 1.40, 95% CI 1.29-1.52, p=<0.001). Pulmonary hypertension was associated with a 40% higher mortality risk in heart failure patients, though this risk attenuated in recent years.
Synapse has enriched 10 related papers. Consider them for comparative context: